US Stock MarketDetailed Quotes
HOTH Hoth Therapeutics
- 0.9100
- +0.0290+3.29%
Trading Nov 7 15:00 ET
6.28MMarket Cap-587P/E (TTM)
0.9300High0.8825Low67.38KVolume0.9300Open0.8810Pre Close60.68KTurnover0.99%Turnover RatioLossP/E (Static)6.90MShares1.730052wk High0.67P/B6.22MFloat Cap0.580052wk Low--Dividend TTM6.84MShs Float347.0000Historical High--Div YieldTTM5.39%Amplitude0.5800Historical Low0.9000Avg Price1Lot Size
About Hoth Therapeutics Company
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
Company Profile
SymbolHOTH
Company NameHoth Therapeutics
Listing DateFeb 15, 2019
Issue Price5.60
Founded2017
CEOMr. Robb Knie
MarketNASDAQ
Employees6
Fiscal Year Ends12-31
Address590 Madison Avenue,21st floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10020
Phone1-646-756-2997
Company Executives
- Name
- Position
- Salary
- Robb Knie
- Chairman of the Board, President and Chief Executive Officer
- 868.82K
- David S. Briones
- Chief Financial Officer and Principal Accounting Officer
- --
- Wayne D. Linsley
- Independent Director
- 65.21K
- Graig Springer
- Independent Director
- 65.21K
- David B. Sarnoff
- Independent Director
- 65.21K
- Dr. Jeff Pavell, M.D.
- Independent Director
- 65.21K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data